Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, today reported preliminary data from the Company’s ongoing extension study of a Phase I/II clinical trial with its lead product Glassia® to treat pediatric patients with a recently diagnosed type 1 diabetes (T1D).
http://www.news-medical.net/news/20131031/Kamada-announces-new-data-from-Glassia-Phase-III-trial-study-in-pediatric-patients-with-type-1-diabetes.aspx